Androgen receptors respond to tamoxifen

Fallleaves

This is just an abstract; have to pay to access the entire article, so I'm not sure the size of this study.

Tamoxifen was given to ER- and TN BC patients who tested positive for androgen receptors (AR) for 2 to 5 years. They were monitored for 15 years for recurrence. For the ER- patients that were AR +, tamoxifen reduced recurrence by 66%, and for TN patients that were AR +, tamoxifen reduced recurrence by 88%. On the other hand giving tamoxifen to those with ER-, and AR- tumors increased recurrence by nearly 3 times the rate of patients not getting tamoxifen, and for TN, AR- patients tamoxifen increased recurrence by 4 times. So pretty extreme impacts in both directions.

http://www.ncbi.nlm.nih.gov/pubmed/26742006